TY - JOUR
T1 - Kidney cancer, version 1.2021
T2 - Featured updates to the nccn guidelines
AU - Motzer, Robert J.
AU - Jonasch, Eric
AU - Boyle, Shawna
AU - Carlo, Maria I.
AU - Manley, Brandon
AU - Agarwal, Neeraj
AU - Alva, Ajjai
AU - Beckermann, Katy
AU - Choueiri, Toni K.
AU - Costello, Brian A.
AU - Derweesh, Ithaar H.
AU - Desai, Arpita
AU - George, Saby
AU - Gore, John L.
AU - Haas, Naomi
AU - Hancock, Steven L.
AU - Kyriakopoulos, Christos
AU - Lam, Elaine T.
AU - Lau, Clayton
AU - Lewis, Bryan
AU - Madoff, David C.
AU - McCreery, Brittany
AU - Michaelson, M. Dror
AU - Mortazavi, Amir
AU - Nandagopal, Lakshminarayanan
AU - Pierorazio, Phillip M.
AU - Plimack, Elizabeth R.
AU - Ponsky, Lee
AU - Ramalingam, Sundhar
AU - Shuch, Brian
AU - Smith, Zachary L.
AU - Somer, Bradley
AU - Sosman, Jeffrey
AU - Dwyer, Mary A.
AU - Motter, Angela D.
N1 - Funding Information:
This activity is supported by educational grants from AstraZeneca; Celgene Corporation; Coherus BioSciences; Genentech, a member of the Roche Group; and TESARO, a GSK Company. This activity is supported in part by an educational grant from Bayer Healthcare Pharmaceuticals. This activity is supported by an independent medical education grant from Bristol-Myers Squibb. This activity is supported by a medical education grant from Exelixis, Inc. This activity is supported by an independent educational grant from Merck & Co., Inc.
Publisher Copyright:
© 2020 Harborside Press. All rights reserved.
PY - 2020/9
Y1 - 2020/9
N2 - The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on recent updates to the guidelines, including changes to certain systemic therapy recommendations for patients with relapsed or stage IV RCC. They also discuss the addition of a new section to the guidelines that identifies and describes the most common hereditary RCC syndromes and provides recommendations for genetic testing, surveillance, and/or treatment options for patients who are suspected or confirmed to have one of these syndromes.
AB - The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on recent updates to the guidelines, including changes to certain systemic therapy recommendations for patients with relapsed or stage IV RCC. They also discuss the addition of a new section to the guidelines that identifies and describes the most common hereditary RCC syndromes and provides recommendations for genetic testing, surveillance, and/or treatment options for patients who are suspected or confirmed to have one of these syndromes.
UR - http://www.scopus.com/inward/record.url?scp=85090506174&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2020.0043
DO - 10.6004/jnccn.2020.0043
M3 - Article
C2 - 32886895
AN - SCOPUS:85090506174
SN - 1540-1405
VL - 18
SP - 1160
EP - 1170
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 9
ER -